- Home
- DMAC vs SLND Comparison
DMAC vs SLND Comparison
Compare DMAC & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- SLND
- Stock Information
- Founded
- DMAC 2000
- SLND 1900
- Country
- DMAC United States
- SLND United States
- Employees
- DMAC N/A
- SLND N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- SLND Military/Government/Technical
- Sector
- DMAC Health Care
- SLND Industrials
- Exchange
- DMAC Nasdaq
- SLND Nasdaq
- Market Cap
- DMAC 178.0M
- SLND 175.8M
- IPO Year
- DMAC N/A
- SLND N/A
- Fundamental
- Price
- DMAC $3.76
- SLND $4.49
- Analyst Decision
- DMAC Strong Buy
- SLND Strong Buy
- Analyst Count
- DMAC 2
- SLND 1
- Target Price
- DMAC $8.00
- SLND $5.00
- AVG Volume (30 Days)
- DMAC 307.4K
- SLND 72.4K
- Earning Date
- DMAC 08-06-2025
- SLND 08-11-2025
- Dividend Yield
- DMAC N/A
- SLND N/A
- EPS Growth
- DMAC N/A
- SLND N/A
- EPS
- DMAC N/A
- SLND N/A
- Revenue
- DMAC N/A
- SLND $931,568,000.00
- Revenue This Year
- DMAC N/A
- SLND $3.76
- Revenue Next Year
- DMAC N/A
- SLND $1.08
- P/E Ratio
- DMAC N/A
- SLND N/A
- Revenue Growth
- DMAC N/A
- SLND N/A
- 52 Week Low
- DMAC $2.80
- SLND $1.85
- 52 Week High
- DMAC $6.82
- SLND $4.62
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- SLND 71.29
- Support Level
- DMAC $3.48
- SLND $3.66
- Resistance Level
- DMAC $3.99
- SLND $4.62
- Average True Range (ATR)
- DMAC 0.32
- SLND 0.26
- MACD
- DMAC -0.00
- SLND 0.05
- Stochastic Oscillator
- DMAC 41.01
- SLND 87.04
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.